2025-01-15 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Review

**1. Performance vs. S&P 500 (VOO):**

Intuitive Surgical Inc. (ISRG) is a company that manufactures and sells da Vinci surgical systems and related instruments and accessories.

The cumulative return of ISRG is significantly higher than that of the S&P 500 (VOO).  The difference in cumulative returns as of the last data point is 180.3 percentage points. This places it at the 95.8th percentile of its historical relative performance against the S&P 500 based on the provided data, indicating substantial outperformance.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 77.0% | 7.3% | 49.0% | 0.0 | 43.0 |
| 2016-2018  | 89.0% | 8.9% | 71.0% | 0.0 | 57.0 |
| 2017-2019  | 93.0% | 9.8% | 63.0% | 0.0 | 70.0 |
| 2018-2020  | 71.0% | 9.8% | 43.0% | 0.0 | 97.0 |
| 2019-2021  | 113.0% | 9.8% | 42.0% | 0.0 | 128.0 |
| 2020-2022  | 21.0% | 20.6% | 12.0% | 0.0 | 95.0 |
| 2021-2023  | 19.0% | 20.6% | -4.0% | 0.0 | 120.0 |
| 2022-2024  | 128.0% | 20.4% | 95.0% | 0.0 | 186.0 |
| 2023-2025  | 187.0% | 9.9% | 133.0% | 0.0 | 192.0 |


The consistently high CAGR (Compound Annual Growth Rate) demonstrates strong historical performance, although the MDD (Maximum Drawdown) figures indicate periods of significant price decline.  The alpha of 0.0 suggests the stock's performance is largely explained by market movements (Beta), however, the significant outperformance against the S&P 500 suggests a possible flaw in this Beta calculation or a model misspecification.


**2. Recent Price Movement:**

* **Closing Price:** $538.88
* **5-Day Moving Average:** $540.40
* **20-Day Moving Average:** $534.61
* **60-Day Moving Average:** $530.86

The price is slightly below the 5-day moving average, suggesting some minor recent downward pressure.  However, it's above both the 20-day and 60-day moving averages, indicating a potential upward trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 58.37 (Slightly above neutral; not overbought)
* **PPO:** 0.16 (Positive, suggesting bullish momentum)
* **20-Day Relative Strength Change:** +1.1 (Short-term upward trend)
* **Expected Return (2+ years):** 18.4% (significantly above S&P 500)

The technical indicators suggest a relatively neutral to slightly bullish outlook.  The high expected return, compared to the S&P 500, reflects the historical outperformance and the potential for continued growth. The current price of $538.88 does not indicate any extreme price movement (e.g., sharp increase or decrease).

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2024-10-18 | $1.59 | $2.04B      |
| 2024-07-19 | $1.48 | $2.01B      |
| 2024-04-19 | $1.54 | $1.89B      |
| 2023-10-20 | $1.18 | $1.74B      |
| 2024-10-18 | $1.18 | $1.74B      | *(Note: This entry appears duplicated.  Assuming it's an error)*

Revenue shows a generally upward trend, with some slight quarterly fluctuations.  EPS also shows a generally positive trend, although there's some variability.  Further investigation is needed to determine the cause of this fluctuation and confirm the apparent duplicate entry for October 18, 2024.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |
| 2023-09-30 | $1.74B | 66.94% |

Revenue is relatively stable with a slight upward trend. Profit margins are consistently high, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |
| 2023-09-30 | $12.54B | 3.32% |

Equity is steadily increasing, demonstrating strong financial health. ROE (Return on Equity) fluctuates, but remains generally positive, although it has slightly decreased in recent quarters.


**7. Overall Analysis:**

ISRG demonstrates strong historical performance, significantly outperforming the S&P 500. Recent price action suggests a potential upward trend, supported by positive technical indicators and high expected return. While there's some variability in recent earnings and ROE, revenue and profit margins remain consistently high.  The companyâ€™s strong financial position and high profitability are positive signs.  However, a deeper dive into the reasons for EPS and ROE fluctuations, as well as clarification of the duplicated earnings data, is necessary for a complete assessment.  The seemingly contradictory alpha of 0.0 also requires further investigation.  Considering the inherent risks associated with any investment, potential investors should conduct thorough due diligence before making any investment decisions.


**8. Disclaimer:** This analysis is based on the provided data and is for informational purposes only. It does not constitute financial advice.  Investment decisions should be made based on your own research and risk tolerance.
